Aurora Cannabis Inc.

Aurora Cannabis Inc.

6.59
CAD
-0.47
(-6.66%)
-0.18EPS
365.54MMarket Cap
Feb 10Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2024 Y
2025 Y
2026 Y
TTM
Revenue per Share
- -
- -
- -
1.34
7.77
14.41
30.64
27.55
14.5
10.3
6.24
5.27
5.65
4.74
Basic EPS, GAAP
-2.95
-13.55
-14.85
-5.32
-5.58
18.77
-36.63
-336.57
-41.01
-79.92
-1.6
0.03
-2.4
-1.57
Free Cash Flow per Basic Share
-3.35
-25.17
-17.4
-8.05
-16.81
-57.06
-75.69
-70.84
-15.59
-6.63
-1.97
0.02
-0.64
-0.42
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
5.19
8.31
3.87
5.28
71.67
327.06
516.94
186.38
102.88
22.23
10.26
10.09
8.68
7.89
Tangible Book Value per Share
5.19
8.31
3.87
5.28
48.04
124.05
61.57
70.07
39.51
19.85
8.72
8.5
7.7
6.91
Basic Weighted Avg Shares
- -
- -
1
1
2
4
8
10
17
21
43
55
57
60
Sales/Revenue/Turnover
- -
- -
- -
1
18
55
246
269
245
221
270
289
321
286
Operating Margin (%)
- -
- -
- -
-318.97
-53.36
-145.13
-122.61
-171.83
-100.57
-99.11
-11.52
3.61
-14.55
-12.08
Depreciation Expense
- -
- -
- -
1
1
12
88
115
98
94
33
13
14
14
Net Income, GAAP
- -
-2
-10
-6
-13
72
-294
-3,283
-694
-1,718
-69
2
-136
-94
Effective Tax Rate (%)
- -
- -
- -
- -
- -
10.47
- -
- -
- -
- -
- -
13.56
- -
- -
Profit Margin (%)
- -
- -
- -
-397.71
-71.78
130.33
-119.54
-1,221.68
-282.82
-776.02
-25.71
0.55
-42.41
-33.02
Working Capital
1
-2
-6
-3
170
145
224
145
550
614
302
367
331
307
LT Debt
- -
- -
2
4
64
201
395
379
359
236
48
78
18
15
Total Equity
1
2
4
6
219
1,553
4,387
2,123
2,038
662
602
609
512
518
Return on Invested Capital (%)
- -
- -
- -
- -
- -
-8.4
- -
- -
- -
- -
- -
20.56
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
8.35
- -
- -
- -
- -
- -
0.53
- -
- -
Return on Common Equity (%)
-44.49
-148.05
-339.82
-116.86
-11.53
8.14
-9.9
-100.53
-33.15
-127.25
-11.35
0.28
-25.2
-17.97

Capital Structure

CAD

•

in mil. unless spec.
Mar'26
Jun'27
Sep'27
ST Debt
6
6
6
LT Borrowings
- -
- -
- -
LT Finance Leases
18
17
15
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
59
63
66
Market Capitalization
269
251
366

Working Capital

CAD

•

in mil. unless spec.
Mar'26
Jun'27
Sep'27
Total Current Assets
397
393
383
Cash, Cash Equivalents & STI
117
100
84
Accounts Receivable, Net
42
41
55
Inventories
175
188
184
Total Current Liabilities
67
73
77
Payables & Accruals
58
64
67
ST Debt
6
6
6
Deferred Revenue
1
1
- -

Growth Rates

CAD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
427.25%
-19.09%
-15.9%
Free Cash Flow
-315.67%
-827.28%
-3,887.39%
Net Income, GAAP
-883.29%
-1,755.06%
-8,645.82%
Sales/Revenue/Turnover
- -
4.29%
10.97%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

CAD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
83
81
88
91
289
2026
74
79
94
38
321
2027
68
86
- -
- -
- -

Quarterly Earnings Per Share

CAD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
0.1
-0.22
0.52
-0.44
0.03
2026
-0.35
-0.94
0.03
-1.24
-2.4
2027
-0.07
-0.32
- -
- -
- -

Quarterly Dividends Per Share

CAD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
2027
- -
- -
- -
- -
- -

Company Description

CEO
Miguel Martin
Full Time Employees
1,028
Sector
Process industries
Industry
Agricultural commodities/Milling
Address
90B Street SW Edmonton AB Canada T6X 1V8
IPO Date
Sep 26, 2007
Business
Aurora Cannabis Inc. R is a Canada-based medical cannabis producer and supplier, focused on the cultivation, processing, distribution and sale of cannabis and cannabis-derived products for medical and adult-use markets, with a broad brand portfolio and international reach. It operates through wholly owned subsidiaries and strategic investments to deliver premium cannabis products and related services across multiple jurisdictions. The company leverages its in-house genetics, cultivation facilities, extraction technologies, and product development capabilities to offer a diversified product line, including dried flower, oils, soft gels, pre-rolls, and branded consumer products, as well as CBD products and hemp-based offerings where permitted. Aurora maintains an active pipeline of new cultivars and innovations intended to expand its market footprint and optimize yield, quality and consistency. Main products and services: cannabis cultivation and production (medical and recreational), cannabis-derived products (oils, concentrates, vape products, edibles in some markets), branded consumer cannabis and hemp products, distribution and wholesale of cannabis and related accessories, extraction and processing services, genetics and breeding programs, research and development, patient education and clinic support services, home cultivation/support tools and technology platforms for product delivery where applicable, international supply agreements and export arrangements, licensing and brand development for third parties where permitted. Latest major company changes: expands recreational product portfolio through new product launches and continuous brand extensions across Greybeard, San Rafael ’71, and Tasty’s lines; forms strategic partnerships and alliances to broaden distribution and access in international markets; executes forays into additional jurisdictions via acquisitions, joint ventures, or minority investments; announces organizational changes or leadership appointments to support global expansion; advances new cultivars and licensing of genetic innovations to peers in the licensed producer ecosystem. Industry context and structure: operates in the cannabis industry across Canadian and international markets, with Canadian Cannabis and Plant Propagation as core segments in some profiles, and European Cannabis or other regional segments in others; targets medical patients, adult-use consumers, and wholesale distribution channels; geographic footprint includes Canada and international markets with manufacturing and distribution facilities, export arrangements, and partner networks. Founding and headquarters: founded in 2010 (founding year widely cited) and headquartered in Edmonton, Alberta, Canada, with additional principal offices or facilities in other North American regions and select international locations. Substantial subsidiary and affiliate network underpins global operations and brand portfolio; operates through a mix of wholly owned subsidiaries and strategic investments across continents. Notes: The company maintains a diversified portfolio of cannabis brands and products, a robust genetics and breeding program, and a strategy centered on premium, science-driven offerings, geographic diversification, and scalable cultivation and processing capabilities. It prioritizes compliance, patient education, and brand equity as foundational elements of its growth trajectory.

Company News

  • The Big Winner From the Aurora Cannabis-Organigram Deal: Curaleaf

  • Aurora Cannabis Inc. (ACB) Q2 Earnings and Revenues Top Estimates

  • Aurora Cannabis Announces Fiscal 2027 Second Quarter Results

  • Aurora Cannabis Stock: What Organigram's Buyout Means for Investors

  • Curaleaf Issues Statement Regarding Alternative Proposal for Aurora Cannabis

  • Organigram to Acquire Aurora and Establish a Global Cannabis Leader

  • Organigram to Acquire Aurora and Establish a Global Cannabis Leader

  • Organigram outbids Curaleaf with C$561M deal for Aurora Cannabis

  • Sigma Lithium upsizes convertible bond offering to $125 million

  • Aurora Cannabis to Host Second Quarter 2027 Investor Conference Call

  • ACB's Q2 Earnings on Deck: International Medical Cannabis in Focus

  • Aurora Cannabis Announces the Alberta Securities Commission has dismissed Curaleaf's Application and ruled in favour of the Company's At-the-Market Program

  • Aurora Rejects Curaleaf's Higher Bid, But the Takeover Fight Isn't Over

  • Aurora Cannabis Reaffirms Recommendation to Shareholders: REJECT Curaleaf's Revised Hostile Bid; Preserve Opportunities for Future Upside

  • Aurora Cannabis Stock Has Soared 25% Since Curaleaf First Made an Offer to Buy Its Business. Here's Why I Think It Can Go Even Higher

  • Comparing Aurora Cannabis (NASDAQ:ACB) & BeOne Medicines (NASDAQ:ONC)

  • Tilray Brands Sinks 4% as Record Revenue Masks Shrinking Cannabis Sales; Canopy Growth and Aurora Cannabis Ease

  • Aurora Completes Major Expansion of European EU-GMP Manufacturing Facility, More Than Doubling Expected Annual Flower Output

  • Aurora Urges Shareholders to Take No Action to Revised Hostile Bid by Curaleaf as Formal Review Underway

  • Curaleaf's Higher Aurora Bid Raises the Stakes in Cannabis Consolidation